How Celgene and Bristol Myers Squibb Used Volume Restrictions to Delay Revlimid Competition
Investigating the pharmaceutical industry’s drug patenting practices
Dec 2023: Patent Abuse is Front-Page News
I-MAK’s response to the senseless killings of Black people with impunity
As more countries around the world reject unmerited patents for Sovaldi®, I-MAK Files Two New U.S. Patent Challenges on Gilead’s Hepatitis C Portfolio
Argentina Rejects Key Patent on Hepatitis C Drug
Country Watch: Nigeria